1. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Liver

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

3. Checkpoint Inhibitors

4. General Risk for imAEs

5. The Liver

6. Upper Limit of Normal

7. Liver Function Tests

8. Hepatitis

9. What to Exclude When Diagnosing Immune-Mediated Hepatitis

10. Biopsy

11. Hepatitis Grades

12. Management of Grade 1-2 Hepatitis

13. Management of Grade 3-4 Hepatitis

14. Observational Study of Patients Who Developed Immune-Mediated Hepatitis

15. Consulting the Gastroenterologist/ Hepatologist

16. Steroid-Refractory Patients

17. General Safety of Retreatment

18. Restarting Therapy in Patients With Hepatitis

19. PD-1 Inhibitors in Patients With HCC

20. Concluding Remarks

21. Abbreviations